Advertisement
Advertisement

GALT

GALT logo

Galectin Therapeutics Inc.

3.45
USD
Sponsored
+0.23
+7.14%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

3.52

+0.06
+1.88%

Galectin Therapeutics Inc. Profile

About

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts.

Info & Links

CEO

Joel Lewis

Headquarters

4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240
NORCROSS, GA 30071, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.galectintherapeutics.com

Auditor

Cherry Bekaert LLP

Share holders

126

Employees

9

Galectin Therapeutics Inc. Statistics

Valuation Measures

Market Capitalization2

231.49M

Enterprise Value

353.09M

Enterprise Value/EBITDA(ttm)

-21.78

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

--

Return on Invested Capital(ttm)

-387.05%

Return on Assets(ttm)

-164.69%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-16.21M

Net Income Available to Common(ttm)

-26.44M

Diluted EPS(ttm)

-0.41

Share Statistics

Beta (5Y Monthly)

0.41

52-Week Change

-10.16%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

65.86M

Dividend Yield

0.00%

Float4

31.22M

% Held by Insiders

52.60%

% Held by Institutions

11.68%

Balance Sheet

Total Cash(mrq)

14.11M

Total Cash Per Share(mrq)

0.21

Total Debt(mrq)

135.71M

Total Debt/Equity(mrq)

-104.20%

Current Ratio(mrq)

2.15%

Quick Ratio(mrq)

2.15%

Book Value Per Share(mrq)

-1.98

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.06

Free Cash Flow(ytd)

-3.87M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement